Contrast-enhanced ultrasound with SonoVue: Differentiation between benign and malignant focal liver lesions in 317 patients

Journal of Clinical Ultrasound

Volumn 38, Issue 1, 2010, Pages 1-9

  Von Herbay, Alexandra ^a   Westendorff, Julia ^a   Gregor, Michael ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Contrast agent; HCC; Hemangioma; Liver; Metastasis; SonoVue; Ultrasound

Indexed keywords

CONTRAST AGENT BR1; CONTRAST MEDIUM; DIAGNOSTIC AGENT; PHOSPHOLIPID; SULFUR HEXAFLUORIDE;

ARTICLE; BILE DUCT CARCINOMA; DIFFERENTIAL DIAGNOSIS; ECHOGRAPHY; EVALUATION; FEMALE; HUMAN; IMAGE ENHANCEMENT; LIVER; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER TUMOR; MALE; METASTASIS; METHODOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMAGE ENHANCEMENT; LIVER; LIVER DISEASES; LIVER NEOPLASMS; MALE; MIDDLE AGED; PHOSPHOLIPIDS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SULFUR HEXAFLUORIDE;

EID: 74549174608     PISSN: 00912751     EISSN: 10970096     Source Type: Journal    
DOI: 10.1002/jcu.20626     Document Type: Article

References (43)

1. Elsayes KM, Narra VR, Mukundan G, et al. MR imaging of the spleen: spectrum of abnormalities. Radiographics 2005;25:967.
2. Bauer A, Hauff P, Lazenby J, et al. Wideband harmonic imaging: a novel contrast ultrasound imaging technique. Eur Radiol 1999;9:S364.
3. Albrecht T, Hoffmann CW, Schettler S, et al. B-mode enhancement at phase-inversion US with air-based microbubble contrast agent: initial experience in humans. Radiology 2000;216:273.
4. Dill-Macky MJ, Burns PN, Khalili K, et al. Focal hepatic masses: enhancement patterns with SH U 508 A and pulse-inversion US. Radiology 2002; 222:95.
5. Shi WT, Forsberg F. Ultrasonic characterization of the nonlinear properties of contrast microbubbles. Ultrasound Med Biol 2000;26:93.
6. von Herbay A, Vogt C, Willers R, et al. Real-time imaging with the sonographic contrast agent Sono-Vue: Differentiation between benign and malignant hepatic lesions. J Ultrasound Med 2004;23:1557.
7. Strobel D, Kleinecke C, Hansler J, et al. Contrastenhanced sonography for the characterisation of hepatocellular carcinomas-correlation with histological differentiation. Ultraschall in Med 2005;26:270.
8. Nicolau C, Catalá V, Vilana R, et al. Evaluation of hepatocellular carcinoma using SonoVue, a second generation ultrasound contrast agent: correlation with cellular differentiation. Eur Radiol 2004;14:1092.
9. von Herbay A, Vogt C, Häussinger D. Late-phase pulse-inversion sonography using the contrast agent Levovist: differentiation between benign and malignant focal lesions of the liver. AJR Am J Roentgenol 2002;179:1273.
10. Dietrich CF, Ignee A, Trojan J, et al. Improved characterization of histologically proven liver tumours by contrast enhanced ultrasonography during the portal venous and specific late phase of SHU 508A. Gut 2004;53:401.
11. von Herbay A, Vogt C, Häussinger D. Differentiation between benign and malignant hepatic lesions: utility of color stimulated acoustic emission with the microbubble contrast agent Levovist. J Ultrasound Med 2004;23:207.
12. Harvey CJ, Albrecht T. Ultrasound of focal liver lesions. Eur Radiol 2001;11:1578.
13. Strobel D, Hoefer A, Martus P, et al. Phase inversion harmonic imaging versus contrast-enhanced power Doppler sonography for the characterization of focal liver lesions. Intern J Col Dis 2003;18:63.
14. Wilson SR, Burns PN. Liver mass evaluation with ultrasound: the impact of microbubble contrast agents and pulse inversion imaging. Semin Liv Dis 2001;21:147.
15. Kim TK, Choi BL, Han JK, et al. Hepatic tumors: contrast agent-enhancement patterns with pulse-inversion harmonic US. Radiology 2000;216:411.
16. Doerffel Y, Wermke W. Neuroendocrine tumors: characterization with contrast-enhanced ultrasonography. Ultraschall Med. 2008;29:506.
17. Schneider M, Arditi M, Barrau MB, et al. BR 1: a new ultrasonographic contrast agent based on sulphur hexafluoride-filled microbubbles. Invest Radiol 1995;30:451.
18. Schneider M. SonoVue, a new ultrasound contrast agent. Eur Radiol 1999;9:S347.
19. Morel DR, Schwieger I, Hohn L, et al. Human pharmacokinetics and safety evaluation of Sono-Vue, a new contrast agent for ultrasound imaging. Invest Radiol 2000;35:80.
20. Correas JM, Burns PN, Lai X, et al. Infusion versus bolus of an ultrasound contrast agent: in vivo dose-response measurements of BR 1. Invest Radiol 2000;35:72.
21. Campani R, Calliada F, Bottinelli O, et al. Contrast media in ultrasonography. Hepatic focal lesions. Radiol Med 1998;95:47.
22. Morel DR, Schwieger I, Hohn L, et al. Human pharmacokinetics and safety evaluation of Sono-Vue, a new contrast agent for ultrasound imaging. Invest Radiol 2000;35:80.
23. Hohmann J, Skok J, Puls R, et al. Characterization of focal liver lesions with contrast-enhanced low MI real time ultrasound and SonoVue. RöFo Fortschr Röntgenstr 2003;175:835.
24. EFSUMB. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS)-Update 2008. Ultraschall in Med 2008;29:28.
25. Romanini L, Passamonti M, Aiani L, et al. Economic assessment of contrast-enhanced ultrasonography for evaluation of focal liver lesions: a multicentre Italian experience. Eur Radiol 2007;17 Suppl 6:F99.
26. Dai Y, Chen MH, Yin SS, et al. Focal liver lesions: can SonoVue-enhanced ultrasound be used to differentiate malignant from benign lesions? Invest Radiol 2007;42:596.
27. Bartoletta TV, Taibbi A, Galia M, et al. Characterization of hypoechoic focal hepatic lesions in patients with fatty liver. Diagnostic performance and confidence of contrast-enhanced ultrasound. Eur Radiol 2007;17:650.
28. Jung EM, Clevert DA, Schreyer AG. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: a prospective controlled two-center study. World J Gastroenterol 2007;13:6356.
29. Xu HX, Liu GJ, Lu MD, et al. Characterization of small focal liver lesions using real-time contrast-enhanced sonography; diagnostic performance analysis in 200 patients. J Ultrasound Med 2006; 25:349.
30. Nicolau C, Vilana R et al. Importance of evaluation all vascular phases on contrast-enhanced sonography in the differentiation of benign from malignant focal liver lesions. AJR Am J Roentgenol 2006;186:158.
31. Quaia E, Calliada F. Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence. Radiology 2004;232:420.
32. von Herbay A, Vogt C, Willers R, et al. Real-time imaging with the sonographic contrast agent Sono-Vue: differentiation between benign and malignant hepatic lesions. J Ultrasound Med 2004;23:1557.
33. Dai Y, Chen MH. Fan ZH, et al. Diagnosis of small hepatic nodules detected by surveillance ultrasound in patients with cirrhosis: Comparison between contrast-enhanced ultrasound and contrast-enhanced helical computed tomography. Hepatol Rad 2008;38:281.
34. Gómez-Rodriguez RA, Artaza-Varasa T, González de Frutos C, et al. Value of contrast-enhanced ultrasound in the diagnosis of hepatocarcinoma in focal lesions detected in patients with liver disease. Gastroenterol Hepatol 2007;30:381.
35. Ding H, Wang WP, et al. Imaging of focal liver lesions: low-mechanical-index real-time ultrasonography with SonoVue. J Ultrasound Med 2005; 24:285.
36. Xu HX, Liu GJ, et al. Characterization of focal liver lesions using contrast-enhanced sonography with a low mechanical index mode and a sulfur hexafluoride-filled microbubble contrast agent. J Clin Ultrasound 2006;34:261.
37. Mörk H, Ignee A, Schuessler G, et al. Analysis of neuroendocrine tumour metastases in the liver using contrast enhanced ultrasonography. Scand J Gastroenterol 2007;42:652.
38. Dietrich CF, Schuessler G, Trojan J, et al. Differentiation of focal nodular hyperplasia and hepatocellular adenoma by contrast-enhanced ultrasound. Br J Radiol 2005;78:704.
39. Dietrich CF, Mertens JC, Braden B, et al. Contrast-enhanced ultrasound of histologically proven liver hemangiomas. Hepatology 2007;45:1139.
40. von Herbay A, Schick D, Horger M, et al. Low-MIsonography with the contrast-agent SonoVue in the diagnosis of infarction of the spleen, kidney, liver and pancreas. Ultraschall in Med 2006; 27:445.
41. Rahbin N, Siösteen AK, Elvin A, et al. Detection and characterization of focal liver lesions with contrast-enhanced-ultrasonography in patients with hepatitis C-induced liver cirrhosis. Acta Radiol 2008;49:251.
42. Bartolotta TV, Midiri M, et al. Characterization of benign hepatic tumors arising in fatty liver with SonoVue and pulse inversion US. Abdom Imaging 2007;32:84.
43. Facciolo N, D'Onafrio M, Comai A, et al. Contrast-enhanced ultrasonography in the characterization of benign focal liver lesions: activitybased cost analysis. Radiol Med (Torino) 2007; 116:810.